←Back to News & Press releases The Swedish national healthcare region of Östergötland signs central agreement with Airsonett for treatment with TLA for patients with severe allergic asthma

The Swedish national healthcare region of Östergötland signs central agreement with Airsonett for treatment with TLA for patients with severe allergic asthma

July 8, 2019

The expert group for respiratory organs in the region of Östergötland has since 2016 recommended TLA as a complementary treatment for adults and children over 6 with severe asthma, who, despite optimal medication, have uncontrolled asthma. However, the prescription was previously limited to the allergy center in Linköping. With the new central agreement, it is possible to prescribe TLA in the whole healthcare region of Östergötland, which will attribute to fair and even care throughout the entire region.

“The agreement with the region of Östergötland is further proof of the increased acceptance of the treatment with Airsonett TLA in healthcare in Sweden. We expect that 2-3 larger regions in Sweden will sign similar agreements with us during autumn”, says Anders Due-Boje, CEO Airsonett AB.


About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.


For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu


About Airsonett
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett® Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett® Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep. Airsonett® Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett® Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit www.airsonett.eu